Conspicuity of prostate cancer lesions diminished by Dutasteride

/
Conspicuity of prostate cancer lesions diminished by Dutasteride

This prospective, randomised dual-blind study showed an increase in ADC and a decrease in conspicuity of prostate cancer lesions in men undergoing therapy with dutasteride. 

Giganti F, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Gambarota G, Whitcher B, Castro R, Emberton M, Allen C, Kirkham A. MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. Eur Radiol. 2017 May 18. doi: 10.1007/s00330-017-4858-0. [Epub
ahead of print] PubMed PMID: 28523355

Read More

PSA-Density: easily obtainable clinical parameter to help excluding significant prostate cancer.

/
PSA-Density: easily obtainable clinical parameter to help excluding significant prostate cancer.

The study shows an increase in the NPV for exclusion of significant prostate cancer when PSA-Density is included as a parameter into the PIRADS-algorithm. 

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA. The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction. J Urol. 2017 Mar 31. [Epub ahead of print] 

Read More

Pulse sequences necessary for recurrence detection after Radiotherapy

/
Pulse sequences necessary for recurrence detection after Radiotherapy

MP MRI of the prostate in detection of recurrent prostate cancer after Radiotherapy: Which sequences are necessary?

Donati OF, Jung SI, Vargas HA, Gultekin DH, Zheng J, Moskowitz CS, Hricak H, Zelefsky MJ, Akin O. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology. 2013 Aug;268(2):440-50

Read More